Provided by Tiger Trade Technology Pte. Ltd.

QYUNS-B

17.290
-0.190-1.09%
Volume:37.80K
Turnover:652.96K
Market Cap:3.86B
PE:12.26
High:17.300
Open:17.290
Low:17.050
Close:17.480
52wk High:33.920
52wk Low:13.210
Shares:223.00M
HK Float Shares:223.00M
Volume Ratio:0.52
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.410
ROE:101.58%
ROA:23.84%
PB:3.82
PE(LYR):12.26
PS:3.21

Loading ...

QYUNS-B Reports No Changes in Share Capital, Confirms Ample Public Float for September 2026

Bulletin Express
·
Yesterday

Qyuns Therapeutics' Oturkibart Shows Sustained Efficacy in Phase III Trial

MT Newswires Live
·
Oct 02

Qyuns Therapeutics Posts Strong Phase III Data for Oturkibart in Prurigo Nodularis; Results Spotlighted at EADV 2026

Bulletin Express
·
Oct 02

QYUNS-B Releases Updated Director Line-Up and Board Committee Assignments

Bulletin Express
·
Sep 22

Hong Kong Stock Movers | QYUNS-B (02509) Jumps Over 9% in Morning Trade, BD Achievements Concentrated, First Product Sees Commercial Ramp-Up

Stock News
·
Sep 14

QYUNS-B Reports Zero Share Movements, Affirms 25%+ Public Float in August 2026 HKEX Return

Bulletin Express
·
Sep 04

Autoimmune Drug Leader Delivers on Long-Term Vision: QYUNS-B's Revenue Doubling and the Dual-Engine Growth Strategy

Stock News
·
Aug 21

Qyuns Therapeutics (SEHK:2509) Stock Turns Profitable While Forecasts Cloud The Outlook

Simply Wall St.
·
Aug 21

QYUNS-B (02509) Posts Interim Net Profit of RMB 203 Million, Reversing Year-Ago Loss as Its "QYUNS 1.0" Strategy Takes Shape

Stock News
·
Aug 19

QYUNS Interim: Licensing Windfall Drives Turn-Round to RMB198.57 Million Profit, Revenue Doubles

Bulletin Express
·
Aug 19

QYUNS Therapeutics Posts HY Adjusted Profit of Rmb202.5 MLN

Reuters
·
Aug 19

Qyuns Therapeutics Hy Revenue 424.1 Mln

THOMSON REUTERS
·
Aug 19

Qyuns Therapeutics Returns to Profit at RMB 198.57 Million in 1H FY26; Revenue More than Doubled to RMB 424.06 Million

Reuters
·
Aug 19

Qyuns Therapeutics to Review 1H26 Interim Results at 19 August Board Meeting

Bulletin Express
·
Aug 07

Qyuns Therapeutics Says China Clears Qx027n Trials for COPD

Reuters
·
Jul 31

Qyuns Therapeutics Co - QX027n Obtains Two Clinical Trial Approvals for Copd and Chronic Rhinosinusitis

THOMSON REUTERS
·
Jul 31

Qyuns Therapeutics Partner Caldera to Merge with Synlogic

MT Newswires Live
·
Jul 30

QYUNS-B (02509) Partner Caldera Therapeutics Plans Nasdaq Listing via Synlogic Merger with $278 Million Concurrent Fundraising Round

Stock News
·
Jul 29

QYUNS-B Updates on Partner Caldera: USD278.00 Million Private Placement Secured Ahead of Planned Nasdaq Listing via Merger with Synlogic

Bulletin Express
·
Jul 29

QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares

Bulletin Express
·
Jul 17